R01AI155023

Synthetic Nanoparticle-Antibody (SNAB) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy - Abstract

In patients with tuberculosis (TB), detrimental immune responses to Mycobacterium tuberculosis (MTB) infection dominate over beneficial immunity, resulting in uncontrolled MTB replication, lung granulomas, and progression to TB disease. Immunosuppressive pathways induced by MTB promote lung pathology and tissue damage and prevent protective immune responses. This suboptimal lung microenvironment can also interfere with antibiotic-mediated killing of MTB. Therefore, in-depth understanding of immunosuppressive mechanisms during TB is critical for developing novel immunomodulatory therapies that tip the balance away from pathogenic responses and towards protective immunity and better bacterial clearance. Thus, host-directed therapies (HDT) that target immunosuppressive pathways in conjunction with anti-TB antibiotics have the potential to improve TB treatment.

Recent studies show that a population of immature myeloid cells that are recruited to the lung after MTB infection contribute to immunosuppression during TB. These cells, termed myeloid-derived suppressor cells (MDSCs), were first described in cancer as negatively regulating tumor microenvironments and suppressing NK cell and T cell cytotoxic functions. Interestingly, accumulation of MDSCs correlates with TB disease pathology, and these cells can also harbor MTB intracellularly. However, in contrast to cancer, the functions of MDSCs in TB are poorly understood.

We hypothesize that MDSCs prevent beneficial innate and adaptive immune responses to MTB infection by suppressing T cell, NK cell, and macrophage functions. We further hypothesize that depleting MDSCs in MTB-infected mice will enhance immune responses to MTB in the lung and significantly improve TB treatment efficacy. We have developed a versatile and effective approach to deplete MDSCs in the lung via novel multivalent synthetic nanoparticle antibodies (SNABs) that specifically target and deplete MDSCs through antibody-like killing mechanisms.

In this MPI-R01 application, we combine expertise in TB pathogenesis and immunology research (Rengarajan, Emory) with expertise in immuno-engineering and nanotherapeutics (Roy, Georgia-Tech) to investigate the role of MDSCs in TB disease progression and pathology, and regulating immunity to TB, and to explore MDSCs as targets of HDT for TB. We will investigate the following specific aims:

Aim 1. Evaluate how depleting MDSCs using SNABs impacts TB disease progression.
Aim 2. Investigate how MDSCs suppress immune responses to MTB infection.
Aim 3. Test the hypothesis that depletion of MDSCs will enhance the efficacy of anti-TB treatment.

Together, these studies will advance our understanding of how MDSCs suppress immunity to TB and provide insights into MDSCs as targets for adjunctive HDTs.

Emory University

NOT APPLICABLE

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Georgia United States

State-Wide

Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed) (PAR-19-357)

Amendment Since initial award the total obligations have increased 331% from $836,957 to $3,610,454.